Key Highlights
- Anatara Lifesciences(ASX:ANR) is progressing manufacture of a demonstration batch of approximately 10,000 capsules of compound AOC
- Pre-clinical studies showed compound AOC significantly attenuated weight regain after cessation of injectable semaglutide (p<0.019)
- The compound also showed a significant reduction in perigonadal fat weight (p=0.024), regardless of body weight
- Cash at quarter end was $551,000, with the R&D tax incentive rebate of $318,000 received during the quarter
Anatara Lifesciences Ltd(ASX:ANR) is advancing its anti-obesity project toward commercial readiness by Manufacturing a demonstration batch of compound AOC, following pre-clinical studies that showed the compound significantly reduced weight regain after cessation of injectable semaglutide.
The Adelaide-based health products company reported in its Q1 FY27 activities report that it has concluded further pre-clinical work is not required, and that a clinical trial would be unlikely to further the understanding of the mechanism of action based on an extensive literature review.
What Are the Anti-Obesity Pre-Clinical Results?
Pre-clinical studies conducted at the University of Newcastle tested compound AOC in a mouse model of diet-induced obesity. The results showed AOC significantly attenuated weight regain following the cessation of injectable semaglutide, with a p-score of less than 0.019.
Additionally, compared to vehicle (placebo), AOC demonstrated a significant reduction in perigonadal fat weight (n=12, p=0.024). Perigonadal fat is considered highly indicative of visceral fat deposits and metabolic conditions. This reduction was observed regardless of body weight, suggesting the compound may reduce visceral fat volumes.
The compound is recognised as Generally Regarded As Safe (GRAS) and is being developed as a complementary medicine or nutraceutical targeting weight loss maintenance and limiting rebound weight gain after stopping contemporary medications such as GLP-1 agonists.
What Are the Next Steps for AOC?
The company is identifying a suitable manufacturing partner to produce approximately 10,000 capsules — representing more than 100 patient-months of supply. The demonstration batch will be used for stability testing and registered for human use in sales and marketing. Post-marketing assessment through an open-label trial remains within the project scope.
The company spent more than $350,000 on the proof-of-concept studies for the anti-obesity project.
What Is Anatara's Financial Position?
Cash at the end of the quarter was $551,000, up from $471,000 at 30 June. The R&D tax incentive rebate of $318,000 was received during the quarter. Directors have agreed to reduce cash payment of fees to 60% of current remuneration until further notice, with 40% to be compensated through future Equity issuance.
Where Does Anatara Stand Going Forward?
The company continues to assess potential transactions and strategic opportunities, with particular focus on projects addressing areas of significant unmet medical need. Commercial interest in its GaRP project intellectual property also continues.






Please wait processing your request...